|
Orthologous residues
|
|
DLC1 (human): S766‑p, DLC1 (mouse): S331‑p, DLC1 iso2 (mouse): S365‑p, DLC1 (rat): S330‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Cellular systems studied:
cell lines, primary cells
|
|
Species studied:
hamster, rat
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
transfection of constitutively active enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
U0126
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
wortmannin
|
insulin
|
|
|
no effect upon treatment-induced increase
|
|
|
U0126, wortmannin
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
rapamycin
|
insulin
|
|
|
no effect upon treatment-induced increase
|
|
|
insulin
|
|
|
|
increase
|
|
|
wortmannin
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
U0126
|
insulin
|
|
|
no effect upon treatment-induced increase
|
|
|
